EuroBiotech: More Articles of Note

Newspapers
(NS Newsflash/CC BY 2.0)

> BioLineRx presented overall survival data from a phase 2a trial of BL-8040 in acute myeloid leukemia. Median overall survival across all dosing levels was 9.1 months. Statement

> Idorsia detailed plans to start a pivotal trial of clazosentan in patients who have suffered subarachnoid hemorrhages. Release 

> Microbiotica has teamed up with the University of Adelaide to develop a defined bacterial product for ulcerative colitis. Statement 

> GammaDelta Therapeutics appointed Michael Koslowski, M.D., as CMO. Koslowski is the former CMO of Mission Therapeutics. Release   

> NeuroVive outlicensed a treatment for Leber's hereditary optic neuropathy to BridgeBio Pharma’s new subsidiary. The deal is worth up to $60 million to NeuroVive. Statement

> Compugen raised $21 million in a registered direct offering. Release